Margaret A. Tempero, MD

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of molecular profiling in pancreatic cancer.

Margaret A. Tempero, MD, director of the Pancreas Center and the Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the importance of germline testing in pancreatic cancer.

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses screening tools used for patients at high risk for pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the outlook for immunotherapies in pancreatic cancer.